东诚药业(002675.SZ)获得177Lu-LNC1009注射液临床试验批准通知书

Core Viewpoint - Dongcheng Pharmaceutical has received approval from the National Medical Products Administration of China for clinical trials of its drug 177Lu-LNC1009, indicating a significant step forward in its product development pipeline [1] Group 1 - Dongcheng Pharmaceutical's subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., is the entity that received the clinical trial approval [1] - The clinical trials for 177Lu-LNC1009 are set to commence shortly, which may enhance the company's market position in the biopharmaceutical sector [1]